

# A naturally occurring 4-bp deletion in the intron 4 of *p53* creates a spectrum of novel *p53* isoforms with anti-apoptosis function

Hui Shi<sup>1</sup>, Ting Tao<sup>1</sup>, Delai Huang<sup>1</sup>, Zhao Ou<sup>2</sup>, Jun Chen<sup>2</sup> and Jinrong Peng<sup>1,\*</sup>

<sup>1</sup>MOE Key Laboratory for Molecular Animal Nutrition, College of Animal Sciences, Zhejiang University, 866 Yu Hang Tang Road, Hangzhou 310058, China and <sup>2</sup>College of Life Sciences, Zhejiang University, 866 Yu Hang Tang Road, Hangzhou 310058, China

Received September 04, 2014; Revised December 15, 2014; Accepted December 18, 2014

## ABSTRACT

**p53 functions as a tumor suppressor by transcriptionally regulating the expression of genes involved in controlling cell proliferation or apoptosis. p53 and its isoform  $\Delta 133p53/\Delta 113p53$  form a negative regulation loop in that p53 activates the expression of  $\Delta 133p53/\Delta 113p53$  while  $\Delta 133p53/\Delta 113p53$  specifically antagonizes p53 apoptotic activity. This pathway is especially important to safeguard the process of embryogenesis because sudden activation of p53 by DNA damage signals or developmental stress is detrimental to a developing embryo. Here we report the identification of five novel p53 isoforms. p53 $\beta$  is generated due to alternative splicing of the intron 8 of p53 while the other four, namely, TA2p53, TA3p53, TA4p53 and TA5p53, result from the combination of alternative splicing of intron 1 (within intron 4 of the p53 gene) of the  $\Delta 113p53$  gene and a naturally occurring CATT 4 bp deletion within the alternative splicing product in zebrafish. The CATT 4 bp deletion creates four translation start codons which are in-frame to the open reading frame of  $\Delta 113p53$ . We also show that TAp53 shares the same promoter with  $\Delta 113p53$  and functions to antagonize p53 apoptotic activity. The identification of  $\Delta 113p53$ /TA2/3/4/5p53 reveals a pro-survival mechanism which operates robustly during embryogenesis in response to the DNA-damage condition.**

## INTRODUCTION

p53 is a pan-transcription factor that regulates diverse biological and cellular processes (1,2). p53 plays its role by regulating the expression of hundreds of genes in response to different internal or external stimuli (3). The identi-

cation of p53 isoforms marks a new era for the study of the p53 pathway and the dimension of the complexity of p53 function is further expanded by the involvement of p53 isoforms (4,5). Thirteen p53 human isoforms have been identified and these isoforms have been implicated to regulate p53 function in different ways (5,6). Human  $\Delta 133p53$  and its zebrafish counterpart  $\Delta 113p53$  belong to a special type of p53 isoforms whose expression is initiated by using intron 4 of the *p53* gene as its promoter (7,8). Previous studies have shown that the transcriptional expression of  $\Delta 113p53/\Delta 133p53$  totally depends on the full-length p53 and the function of  $\Delta 113p53/\Delta 133p53$  protein is to antagonize the p53 apoptotic activity selectively (9–11).  $\Delta 113p53/\Delta 133p53$  functions at least in part through its interaction with p53 (9,12). Human  $\Delta 133p53$  has been found to be highly expressed in certain cancer cells (6,13–15) while the expression of the zebrafish  $\Delta 113p53$  is induced by morpholino injection (16) or by mutations in genes including *def* (1) and *sec13* (17).

Digestive organ expansion factor Def is a nucleolar protein and loss-of-function of Def in the *def<sup>hi429/hi429</sup>* mutant results in hypoplastic digestive organs in a cell autonomous manner (7,18). The p53 pathway is activated in *def<sup>hi429/hi429</sup>* that in turn up-regulates the expression of  $\Delta 113p53$  (9). Recently, it has been shown that Def and Capn3 form a complex to mediate p53 degradation specifically in the nucleoli, which explains why p53 protein is accumulated in the nucleoli of *def<sup>hi429/hi429</sup>* mutant cells (1). Here we report the identification of five novel p53 isoforms, namely, p53 $\beta$ , TA2p53, TA3p53, TA4p53 and TA5p53. p53 $\beta$  is generated due to alternative splicing of the intron 8 of p53 while TA2/3/4/5p53 are derived from a naturally occurring 4 bp genomic deletion in the intron 1 of the  $\Delta 113p53$  gene (part of the intron 4 of the *p53* gene), which creates four new translation start codons in the product of alternative splicing of the intron 1 of the  $\Delta 113p53$  gene. We focused on studying the function of TAp53 isoforms and showed that these new isoforms

\*To whom correspondence should be addressed. Tel/Fax: +86 571 88982233; Email: pengjr@zju.edu.cn

Present address: Ting Tao, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

function to antagonize the p53 apoptotic function in a way similar to that of  $\Delta 113p53$ .

## MATERIALS AND METHODS

### Zebrafish lines and maintenance

Zebrafish were raised and maintained according to the standard procedure described in ZFIN ([http://zfin.org/zf\\_info/zfbook/zfbk.html](http://zfin.org/zf_info/zfbook/zfbk.html)). The *def<sup>hi429</sup>* mutant line was provided by Prof Nancy Hopkins at Massachusetts Institute of Technology. Two pairs of primers derived from *lacZ* and *def* were used to genotype the *def<sup>hi429</sup>* mutant (7). The *p53<sup>-/-</sup>* mutant allele *tp53<sup>M214K</sup>* line was provided by Prof Thomas Look at Harvard Medical School. *Tg( $\Delta 113p53:gfp$ )* transgenic fish was as described (9). CATT genotypes were identified by sequencing, the primer pair 5'- GGCGAACATTGGAGGG-3' and 5'- AAAACACCCTAATGCGTCTTCAC-3' were used for PCR and the primer 5'- CACAGAACATAAATAAATAACAC-3' was used for sequencing.

### Morpholinos

Morpholinos were purchased from Gene Tools. *def*-MO,  $\Delta 113p53$ -MO<sup>ATG</sup> and the human  $\beta$ -globin antisense morpholino (st-MO) were used as described previously (7). *TAp53*-MO<sup>sp1</sup> (5'- TTTAATCACACTTACATTCAAGCCT-3') was designed to target the splice junction between exon 1 and intron 1 of the  $\Delta 113p53$  transcript.

### RNA and protein analysis

Total RNA was extracted from different samples using TRIzol reagent (Invitrogen). For real-time quantitative polymerase chain reaction (qPCR), total RNA was treated with DNase I prior to reverse transcription and purified with RNeasy mini kit (Qiagen). First strand cDNA was synthesized using M-MLV Reverse Transcriptase (Invitrogen). The qPCR was performed on CFX96TM Real-Time System (Bio-Rad) using SsoFast EvaGreen Supermix (Bio-Rad) according to the manufacturer's instructions. Primer pairs used for qPCR were listed in Supplementary Table S1.

The methods used for protein extraction from zebrafish embryos are as described previously (9). Protein electrophoresis and western blot were performed according to the instructions provided by the manufacturers (19).

### TUNEL assay and embryo viability counting

*tp53<sup>M214K</sup>* mutant embryos injected with either p53 or  $\Delta 113p53$  mRNA were harvested for Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assays at 10 hours post injection (hpi). The survival rate for each treatment was counted at 24 hpi. CATT<sup>+/+</sup> or CATT<sup>-/-</sup> AB embryos were treated with  $\gamma$ -ray at 24 hpf at a dosage of 24 gray (Gy). Embryos at 8 h post-treatment were harvested for western and the survival rate for each treatment at 5 days post-treatment was counted.


## Antibodies

The zf-p53 mouse monoclonal antibody A7-C10 was used as previously described (1). The zf-p53 N-terminal mouse monoclonal antibody 9.1 was purchased from abcam (ab77813). Rabbit monoclonal antibody (EPR1977Y) against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was from Epitomics (#2251-1), and rabbit polyclonal antibody against  $\beta$ -actin (#4967) was from Cell Signaling Technology.

## RESULTS

### Identification of a p53 alternative splicing isoform p53 $\beta$

During the course of comparing the p53 and  $\Delta 113p53$  protein levels in the *def<sup>hi429/hi429</sup>* mutant using a monoclonal antibody (A7-C10) specifically against the zebrafish p53, we noted that, in addition to the expected p53 and  $\Delta 113p53$  bands, two extra bands, one with a molecular weight of  $\sim 35$  kD and another  $\sim 45$  kD, were detected (1). These two extra bands were also observed in the embryos treated with camptothecin (1,12). The higher extra band (45 kD) presumably corresponds to  $\Delta N$ -p53 reported previously (20). To reveal the nature of the 35 kD band, we first performed a reverse transcriptase-PCR (RT-PCR) to amplify the cDNA fragment between the exon 5 and exon 10 (this region corresponds to the production of human p53 $\beta$  and p53 $\gamma$  through alternative splicing) (8) (Figure 1A and Supplementary Table S1) and sequenced the PCR product to check whether there is an alternative splicing in the 3'-end of zebrafish p53 corresponding to the human p53 $\beta$  or p53 $\gamma$  (8). We obtained a PCR product (Figure 1B) which, when compared with the p53 full-length cDNA, contained an additional 85 bp originated from the intron 8 of the p53 gene due to alternative splicing (Figure 1C). This transcript is predicted to encode a peptide that retains the N-terminal 275 amino acids of p53 followed by the addition of 19 new amino acids (Figure 1C, Supplementary Figure S1). This new transcript is different from the GenBank sequence NC\_007116 which contains an additional 12 bp originated from the intron 8 of p53 and has a predicted open reading frame (ORF) that is in-frame to the ORF of p53 (Figure 1C). To confirm that the new transcript is a genuine splicing product we performed an RT-PCR using a forward primer derived from exon 5 and a reverse primer from intron 8. A clear PCR band was obtained (Figure 1D). Sequencing of the PCR product revealed that it is identical to the new transcript (data not shown). The monoclonal antibody A7-C10 is known to recognize the C-terminus of the zebrafish p53, thus it was used to detect both the full-length p53 and  $\Delta 113p53$  (1). In contrast, the monoclonal antibody 9.1 which recognizes the N-terminus of the zebrafish p53, was used to detect the full-length p53 but not  $\Delta 113p53$  because  $\Delta 113p53$  lacks its recognition motif (21). We cloned the PCR product into the expression vector and used the *in vitro* transcribed mRNA derived for injection. We found that this mRNA encoded for a product with much higher molecular weight which was detected by 9.1 but not by A7-C10 (Figure 1E). We designated this new p53 isoform as p53 $\beta$ . However, the expression of p53 $\beta$  protein is undetectable by the treatment of camptothecin (Figure 1E) or  $\gamma$ -ray (Supplementary Figure S2). Based on the above, we



**Figure 1.** Identification of a new zebrafish p53 splicing isoform p53 $\beta$ . (A) Schematic diagram showing the genomic structure of the *p53* gene. White/black boxes, exons (E1–E11); black boxes, p53 ORF; solid line, introns; double slashes, omitted genomic region; black arrow, position and direction of primers; blue arrow head, indicating the translation start codon for  $\Delta 113p53$ . Red dot, stop codon of p53 $\beta$ . (B) Gel picture showing the RT-PCR products produced from WT, *def<sup>hi429/hi429</sup>* and camptothecin-treated embryos at 5 dpf using the *p53*\_ExV\_Fw372 and *p53*\_ExX\_Rv954 primers pair as indicated in (A). (C) Upper panels: alignment of full-length *p53*, NC\_007116 and *p53* $\beta$  cDNA sequences. 85 bp of origin of intron 8 in *p53* $\beta$  was shown and this 85 bp introduces an early stop codon TGA in *p53* $\beta$ . NC\_007116 has an extra 12 bp of intron 8 origin when compared with the full-length *p53*. Lower panels: schematic diagram for comparison of major protein domains between p53 and p53 $\beta$ . (D) Gel picture showing RT-PCR products obtained from WT and camptothecin-treated embryos at 24 hpf using primer pair *p53*\_ExV\_Fw372 (derived from exon 5) and *p53*\_InVIII\_Rv73 (derived from intron 8). (E) Western blot analysis using two different monoclonal antibodies A7-C10 (left panel) and 9.1 (right panel) that specifically recognizes zebrafish p53 proteins, to assess the levels of the p53, p53 $\beta$  and  $\Delta 113p53$  isoforms after mRNA injection. mRNA was injected into embryos at one cell stage and total protein was extracted at 6 hpf. Camptothecin-treated embryos was used as a control.


conclude that the 35 kD protein is not derived from the alternative splicing of the 3'-end (intron 8) of *p53*.

### Identification of $\Delta 113p53$ alternative splicing transcripts

The transcription of  $\Delta 113p53$  is initiated in the intron 4 of the full-length *p53* gene followed by its first intron of ~1 kb in size (7) (Figure 2A). We reckoned that the new 35 kD p53 isoform could have resulted from the alternative splicing of the intron 1 of the  $\Delta 113p53$  gene. To test this hypothesis, we designed a forward primer based on the 5'-upstream sequence of  $\Delta 113p53$  (within the intron 4 of the *p53* gene) and three reverse primers based on the exon2 of  $\Delta 113p53$  (corresponding to the exon 5 of the *p53* gene) (Supplementary Table S1). These three pairs of primers are

expected to amplify part of the  $\Delta 113p53$  cDNA but not of the *p53* cDNA (Figure 2A). We first used the primer pair  $\Delta 113p53$ \_5'UTR\_Fw and *p53*\_ExV\_Rv413 (Supplementary Table S1) in RT-PCR using RNA samples obtained from the wild type (WT) and camptothecin-treated embryos. Two discrete PCR products were observed in the camptothecin-treated embryos, whereas only one faint band was detected in the WT control (Figure 2B). We then used all three primer pairs for RT-PCR using the cDNA templates obtained from *def<sup>hi429/hi429</sup>* mutant and camptothecin-treated embryos, respectively. Again, two discrete PCR products were observed in both *def<sup>hi429/hi429</sup>* and camptothecin-treated embryos (Figure 2C). We recovered the two PCR products by gel extraction for subsequent cloning. Sequencing of the clones containing the lower band revealed that it corre-





**Figure 2.** Identification of  $\Delta 113p53$  splicing transcripts. (A) Schematic diagram showing the genomic structure of the *p53* gene. White/black boxes, exons (E1–E11); E1a box, exon 1 of  $\Delta 113p53$ ; E1b, exon 1 of +36/+32 bp transcript; solid line, introns; double slashes, omitted genomic region; black arrow, position and direction of primers; blue and red arrow heads, indicating the translation start codon for  $\Delta 113p53$  and TA5p53, respectively. TSS,  $\Delta 113p53$  transcription start site. (B and C) RT-PCR analysis of transcripts in WT and camptothecin-treated embryos using the  $\Delta 113p53$  5'UTR\_Fw and *p53*\_ExV\_Rv413 primers pair (B) and in *defhi429* and camptothecin-treated embryos using  $\Delta 113p53$  5'UTR\_Fw and *p53*\_ExV\_Rv413 (p1),  $\Delta 113p53$  5'UTR\_Fw and *p53*\_ExV\_Rv351 (p2) and  $\Delta 113p53$  5'UTR\_Fw and *p53*\_ExV\_Rv318 (p3) three primers pairs (C). (D) Alignment of  $\Delta 113p53$ , +36 bp and +32 bp cDNA sequences. CATT 4 bp (boxed and lettered in red) is deleted in the +32 bp transcript. (E) Western blot analysis of p53 and its isoforms in 36 hpf WT and camptothecin-treated embryos that were injected with either control morpholino (st-MO),  $\Delta 113p53$ -MO<sup>ATG</sup> or TAp53-MO<sup>sp1</sup>. Morpholinos were injected into one-cell stage zebrafish embryos. WT and injected embryos were treated with camptothecin at 24 hpf for 12 h. A7-C10, zebrafish p53 monoclonal antibody. TA2/3/4p53?, the identity of each of these bands in correspondence to TA2p53, TA3p53 and TA4p53 has not been determined. GAPDH was used as a loading control.


sponds to the  $\Delta 113p53$  transcript. Surprisingly, sequencing of the higher PCR product yielded two DNA sequences that differed from a genuine  $\Delta 113p53$  sequence by addition of either 32 bp (+32 bp transcript) or 36 bp (+36bp transcript) originated from the intron 1 of the  $\Delta 113p53$  gene (Figure 2D). Sequence alignment of +36 bp and +32 bp two transcripts revealed that both transcripts are likely to be derived from the same alternative splicing product of  $\Delta 113p53$  and the difference between the +36 bp and +32 bp two transcripts is that the +32 bp transcript lacks CATT 4 bp (Figure 2D and Supplementary Figure S3).

To confirm whether +36/+32 bp transcripts resulted from alternative splicing, we designed a morpholino (TAp53-MO<sup>sp1</sup>) that specifically targets the presumed splicing donor site (Supplementary Figure S3). The injection of TAp53-MO<sup>sp1</sup> abolished the expression of the 35 kD product together with other unidentified bands induced by camptothecin but did not affect on the production of  $\Delta 113p53$  (Figure 2E). In contrast, the injection of  $\Delta 113p53$ -MO<sup>ATG</sup>, which has been shown to knock down the expression of  $\Delta 113p53$  effectively (9), only blocked the expression

of  $\Delta 113p53$  but not the 35 kD product and other unidentified products induced by camptothecin (Figure 2E).

### The naturally occurring CATT 4bp deletion in the intron 1 of the $\Delta 113p53$ gene is inherent in the fish population

As stated above, the difference between the +36 and +32 bp two transcripts is the CATT 4 bp deletion in the +32 bp transcript. To find out the origin of these 4 bp deletion, we extracted genomic DNA from 44 individual AB line fish and amplified the DNA fragment containing this region. The PCR products were sequenced and the result revealed that 17 fish were homozygous for CATT (CATT<sup>+/+</sup>), 9 homozygous for CATT deletion (CATT<sup>-/-</sup>) and 18 heterozygotes (CATT<sup>+/-</sup>) (Figure 3A). In addition, 12 Tübingen adult fish were analyzed and we identified 9 CATT<sup>+/+</sup> and 3 CATT<sup>+/-</sup> individuals (Figure 3A). Therefore, the 4-bp deletion in +32 bp transcript is a naturally occurring deletion that is inherent in the existing AB fish population. We then used the primer pair  $\Delta 113p53$  5'UTR\_Fw and *p53*\_ExV\_Rv318 (Supplementary Table S1) to analyze the transcripts of  $\Delta 113p53$ , +32 bp and +36 bp in CATT<sup>+/+</sup> and CATT<sup>-/-</sup> fish, respectively, after camptothecin treatment.



**Figure 3.**  $\Delta 113p53$  and the +36/+32 bp transcripts share the same promoter. (A) A *CATT* 4 bp deletion is naturally occurring in the intron 1 of  $\Delta 113p53$  in the existing *AB* zebrafish population. Summary of genotyping *CATT*<sup>+/+</sup>, *CATT*<sup>+/-</sup> and *CATT*<sup>-/-</sup> individuals in the randomly selected population. (B) RT-PCR analysis of +36 and/or +32 bp transcripts in embryos treated with or without camptothecin using  $\Delta 113p53$ .5'UTR.Fw and *eGFP*.Rv22 primer pairs. The same primer pair was also used in amplifying the corresponding genomic DNA fragment. (C) Schematic diagram showing the reporter construct in the transgenic fish *Tg*( $\Delta 113p53$ :*eGFP*).  $\Delta 113p53$ .5'UTR.Fw and *eGFP*.Rv22: primers pair used in RT-PCR. White/Black boxes, exons (E1–E5); E1a box, exon 1 of  $\Delta 113p53$ ; E1b, exon 1 of +36/+32 transcript; TSS,  $\Delta 113p53$  transcription start site. (D) RT-PCR analysis of transcripts in *Tg*( $\Delta 113p53$ :*eGFP*) embryos treated with or without camptothecin using the  $\Delta 113p53$ .5'UTR.Fw and *eGFP*.Rv22 primer pairs. (E) Sequence analysis of the RT-PCR product showed that the  $\Delta 113p53$ :*eGFP* transgene also produced a splicing transcript identical to the endogenous  $\Delta 113p53$  gene. Brown arrow head: translation start codon ATG for *eGFP*. *eGFP*.Rv22: reverse primer used in RT-PCR. (F) Sequence alignment analysis of the 5'-RACE products obtained from the camptothecin-treated *Tg*( $\Delta 113p53$ :*eGFP*) transgenic fish using the *eGFP*.Rv99 and *eGFP*.Rv22 as specific reverse primers.

The result showed that  $CATT^{+/+}$  fish produced  $\Delta 113p53$  and +36 bp transcripts, whereas  $CATT^{-/-}$  fish produced the  $\Delta 113p53$  and +32 bp transcripts as expected (Figure 3B). In addition, we confirmed that the alternative splicing of intron 8 also occurs in +32 bp transcript by RT-PCR using a forward primer derived from the exon 1 of  $\Delta 113p53$  and a reverse primer from intron 8 of  $p53$  (data not shown).


### $\Delta 113p53$ and +36/+32 bp transcripts share the same promoter

We previously reported that the  $Tg(\Delta 113p53:eGFP)$  transgenic fish which harbors the reporter gene  $eGFP$  under-driven by the  $\Delta 113p53$  promoter can faithfully recapitulate the response of  $\Delta 113p53$  to the developmental and DNA-damaging signals (9). Knowing that there are two genotypes for the intron 1 of  $\Delta 113p53$ , namely,  $CATT^{+}$  and  $CATT^{-}$ , we first determined the genotype of the intron 1 of  $\Delta 113p53$  fused with the reporter  $eGFP$  and found that the transgene belongs to  $CATT^{+}$ . We surmised that, if the transcription of the +36/+32 bp transcripts shares the same promoter with that of  $\Delta 113p53$ , both  $\Delta 113p53$  and the +36 bp transcript must be transcribed from the  $\Delta 113p53:eGFP$  transgene in the  $Tg(\Delta 113p53:eGFP)$  fish under the DNA damage stress. To test this hypothesis, we used a forward primer in the 5'-upstream sequence of  $\Delta 113p53$  ( $\Delta 113p53\_5'UTR\_Fw$ ) and a reverse primer in the  $eGFP$  gene sequence ( $eGFP\_Rv22$ ) (Figure 3C and Supplementary Table S1) for PCR using the cDNA templates obtained from  $Tg(\Delta 113p53:eGFP)$  embryos. Clearly, two discrete PCR products were obtained in the camptothecin-treated samples, whereas only one weak band was observed in the control embryos (Figure 3D). We recovered the two PCR products by gel extraction for subsequent cloning and sequencing. The result showed that these two products represent the splicing variants of the  $\Delta 113p53:eGFP$  transgene that exactly matches the endogenous  $\Delta 113p53$  and +36 bp transcripts (Figure 3E).

We performed 5'-RACE to determine the transcription start site for the endogenous +36/+32 bp transcripts, however, due to the fact that p53 has many isoforms it was hard to identify and obtain the corresponding 5'-RACE products for the the +36/+32 bp transcripts. As an alternative, we performed 5'-RACE using the cDNA template obtained from camptothecin-treated  $Tg(\Delta 113p53:eGFP)$  embryos with a primer derived from the  $eGFP$  gene (Figure 3C, Supplementary Table S1). We cloned the 5'-RACE products for sequencing. Detailed analysis of the DNA sequence revealed that, the transcription start site for the +36 transcript is nearly identical to that of  $\Delta 113p53$  (Figure 3F) (7). Thus, the transcription of the +36/+32 bp transcripts and  $\Delta 113p53$  was driven by the same promoter.

### TAp53 proteins arise from the CATT 4 bp deletion in the $\Delta 113p53$ alternative splicing transcript

The +36-bp transcript was predicted to encode a product that is identical to that encoded by the  $\Delta 113p53$  transcript, however, the +32-bp transcript adds four new ATG codons which are in frame to the ORF of  $\Delta 113p53$  due to the CATT 4 bp deletion, leading to predicted peptide products of 345, 325, 298 and 289 AA, respectively (Figure 4A and Supple-



**Figure 4.** Determination of the translation start codon for the +32-bp transcript. (A) Upper panel: showing the 5'-leading sequence, highlighting the position of the four new ATG codons (capital letters in red) in the +32-bp transcript which are in-frame to the translation start codon ATG of  $\Delta 113p53$ . Lower panel: showing the 5'-leading sequence of the +36 transcript. Three ATG codons in capital letters are not in-frame to the translation start codon ATG of  $\Delta 113p53$  in the +36 transcript. Solid blue bar with a double slash:  $\Delta 113p53$  ORF sequence; yellow shading: alternatively spliced sequence in +32/+36 transcripts. TGA: translation stop codon. (B) Western blot analysis of p53 and its isoforms in camptothecin-treated embryos injected with or without  $TAp53-MO^{sp1}$ , or in embryos injected with 345AA mRNA. Camptothecin induced the expression of  $\Delta 113p53$  and TAp53 isoforms, whereas the  $TAp53-MO^{sp1}$  effectively knocked down the expression of TAp53 isoforms but not  $\Delta 113p53$ . The 345AA mRNA expressed TA5p53 and other TAp53 isoforms. GAPDH: loading control. (C) Western blot analysis of protein products produced by four different mRNAs derived from the +32-bp transcripts as shown. WT and camptothecin-treated WT embryos were used as the negative and positive control, respectively. (D) Western blot analysis of protein products produced by different mRNAs are shown. Mutagenesis of the 289 ATG in 345AA mRNA abolished the expression of TA5p53 (lane: 289ATG>ATA) while mutagenesis of the  $\Delta 113p53$  ATG in 289AA mRNA abolished the expression of  $\Delta 113p53$  (lane: 113ATG>ATA). In (B–D), monoclonal antibody A7-C10 was used to detect p53 and its isoforms. In (C and D), Coomassie blue staining: loading control. (E) Western blot analysis of p53,  $\Delta 113p53$  and TAp53 isoforms in camptothecin-treated  $CATT^{+/+}$ ,  $CATT^{+/-}$  and  $CATT^{-/-}$  embryos, respectively, using the A7-C10 antibody. TA2/3/4p53?: the identity of each of these bands in correspondence to TA2p53, TA3p53 and TA4p53 has not been determined.



mentary Figure S3). We cloned the +32-bp transcript containing coding sequence for 345 AA product (Supplementary Table S1) and obtained its mRNA by *in vitro* transcription. The +32-bp mRNA was injected into embryos and total proteins were extracted and subjected to western blot analysis. We found that the +32-bp transcript produced a major protein product of the size of 35 kD and also other protein products identical to that observed in the *def<sup>hi429/hi429</sup>* or camptothecin-treated embryos (Figure 4B). Thereafter, we named the new p53 isoforms derived from +32 bp mRNA as TA2p53 (corresponding to 345 AA product), TA3p53 (corresponding to 325 AA product), TA4p53 (corresponding to 298 AA product) and TA5p53 (corresponding to 289 AA product), collectively called TAp53 isoforms.

To determine whether these four new ATG codons in +32 bp transcript are genuinely used in the translation of corresponding TAp53 isoforms, we generated four constructs, namely, 345-, 325-, 298- and 289-*TAp53*, respectively, corresponding to the four new ATG codons in the +32-bp transcripts (Supplementary Table S1), for *in vitro* transcription. The mRNA corresponding to each of these four constructs was injected and total protein was extracted and subjected to western blot analysis. The result showed that the 289-*TAp53* mRNA yielded two protein products identical to those observed in *def<sup>hi429/hi429</sup>* and camptothecin-treated embryos (Figure 4C). Injection of 298-*TAp53* mRNA produced two products, one corresponding to TAp53 plus a new higher band (Figure 4C). The predominant product by 325-*TAp53* mRNA injection produced TA5p53, meanwhile two faint higher bands, one corresponding to the higher band observed by 298-*TAp53* mRNA injection and another being a new band (Figure 4C). Injection of 345-*TAp53* mRNA also produced TA5p53 as the predominant product and a few faint higher bands (Figure 4C). Apparently, protein translation can be initiated from all four ATG codons. However, because all four mRNAs produced TA5p53 as the major product and the 289-*TAp53* is the shortest one, we concluded that TA5p53 is translated by using the ATG for the 289 AA product and ATG<sup>289</sup> is a preferred translation start codon.

To unequivocally prove that TA5p53 is translated from the ATG in 289-*TAp53* unequivocally we mutated the 289 ATG to ATA in the 345-*TAp53* transcript (Supplementary Table S1). This mutant mRNA failed to produce TA5p53 and but produced  $\Delta 113p53$ . When the ATG for  $\Delta 113p53$  translation initiation was mutated to ATA in the 289-*TAp53* transcript, the resultant mutant mRNA was no longer able to produce  $\Delta 113p53$  but only produced TA5p53 (Figure 4D). These results demonstrate that the 289 ATG is responsible for the translation of TA5p53 (Supplementary Figure S4).


Next, we extracted total protein from CATT<sup>+/+</sup> and CATT<sup>-/-</sup> fish, respectively, after camptothecin treatment, and performed western blotting to analyze the expression of  $\Delta 113p53$  and TAp53 protein in these two genotypes. We found that CATT<sup>+/+</sup> fish only produced  $\Delta 113p53$ , whereas CATT<sup>-/-</sup> fish produced  $\Delta 113p53$ , TA5p53 and other isoforms (Figure 4E). Therefore, these TAp53 isoforms are indeed translated into functional proteins.

### TAp53 isoforms are pro-survival factors

Sequence alignment showed that all TAp53 isoforms lack the N-terminal 93 amino acids of the full-length p53 while TA2p53 added 65 extra amino acids, TA3p53 45 extra amino acids, TA4p53 18 extra amino acids and TA5p53 9 extra amino acids at their N-termini (Supplementary Figure S5). We previously showed that  $\Delta 113p53$  selectively antagonizes p53 apoptotic function through Bcl-xl (9). We were intrigued to know the function of the naturally occurring TAp53 isoforms. We first injected *p53*, 345-*TAp53* and 289-*TAp53* (with  $\Delta 113p53$  start codon ATG being mutated to ATA) mRNA, respectively, into one cell stage *p53<sup>M214K</sup>* (*p53* null mutant) embryos and examined the expression of *p21* and *mdm2*. The result showed that the expression of *p21* and *mdm2* was robustly induced by p53 but not by TAp53 isoforms (Supplementary Figure S6A). In addition, TAp53 isoforms failed to activate the expression of *p53* (Supplementary Figure S6B). These results suggest that TAp53 isoforms alone, like  $\Delta 113p53$ , do not transactivate these p53-reponse genes, however, we cannot exclude the possibility that the new isoforms can transactivate other p53-reponse genes or genes other than the ones activated by p53. Next, we co-injected *p53* mRNA with 345-*TAp53* mRNA into one cell stage embryos. As expected, p53 overexpression resulted in a high rate of mortality (~60% embryos died at 24 h post-injection) and co-injection of  $\Delta 113p53$  with p53 significantly reduced the rate of mortality (less than 35% embryos died at 24 h post-injection) (Figure 5A, Supplementary Figure S7). Interestingly, we noted that TAp53 isoforms not only significantly reduced the rate of mortality caused by p53 but also appeared to be more efficient than  $\Delta 113p53$  did (Figure 5A, Supplementary Figure S7). TUNEL assay revealed that these TAp53 isoforms exhibited stronger anti-apoptotic effect than  $\Delta 113p53$  did on p53-mediated cell apoptosis (Figure 5B, Supplementary Figure S8). This data suggests that TAp53 isoforms also conferred anti-apoptotic function, much like the  $\Delta 113p53$  isoform (9). Finally, we exposed the CATT<sup>+/+</sup> and CATT<sup>-/-</sup> fish to  $\gamma$ -ray for comparing their tolerance to the ionizing radiation treatment. Embryos at 24 hpf were irradiated with 24 Gray for 30 min and then allowed to grow in the egg water for another 5 days. We first examined the induction of  $\Delta 113p53$  and TAp53 isoforms expression in CATT<sup>+/+</sup> and CATT<sup>-/-</sup> fish and found that, as expected, the CATT<sup>+/+</sup> fish produced  $\Delta 113p53$  only while the CATT<sup>-/-</sup> fish produced both  $\Delta 113p53$  and TAp53 isoforms (Figure 5C). The survival rate was then recorded in each case. The statistic data showed that the CATT<sup>+/+</sup> fish exhibited a 29% survival rate that was significantly lower than that displayed by the CATT<sup>-/-</sup> fish (46%) (Figure 5D, Supplementary Figure S9). Taken together, our results suggest that the  $\Delta 113p53$  and TAp53 isoforms work together to protect embryos from the DNA damage stress.

### DISCUSSION

Genetic mutations include base substitution, deletion, inversion, duplication and crossover exchanges. Genetic mutations can be harmful, beneficial or neutral, depending on the consequence of the mutation in the genome. In this report, we show that a naturally occurring CATT 4 bp deletion in the intron 1 of the  $\Delta 113p53$  gene (also being part



**Figure 5.** TAp53 isoforms serve as pro-survival factors by antagonizing p53 apoptotic function. (A) Survival rate of *tp53*<sup>M214K</sup> embryos injected with phenol red (control), *p53* mRNA alone, *p53* plus  $\Delta 113p53$  mRNAs and *p53* plus 345-TAp53 mRNAs. Statistical data were obtained from three independent repeats. Over 100 embryos were examined in each repeat. (B) Apoptosis TUNEL assay (red spots) in *tp53*<sup>M214K</sup> embryos at 10 hpf injected with *p53* mRNA alone or co-injected with *p53* and  $\Delta 113p53$  mRNA or *p53* and 345-TAp53 mRNA. Controls: buffer containing Phenol Red injected *tp53*<sup>M214K</sup> embryos. Statistical data were obtained from counting apoptotic cells from 30 to 50 embryos. (C) Western blot analysis of  $\Delta 113p53$  and TAp53 isoforms in embryos 8 h after treatment with or without  $\gamma$ -ray. Embryos were treated with 24 Gray of  $\gamma$ -ray at 24 hpf. (D) Survival rate of embryos 5 days after being treated with  $\gamma$ -ray are shown. Statistical data were obtained from three batches of embryos treated with 24 Gray of  $\gamma$ -ray ( $n > 120$  in each case). In (A) and (D), data are presented as means  $\pm$  standard error. \* $P < 0.05$ , \*\* $P < 0.01$ .

of the intron 4 of the *p53* gene), creates four novel p53 isoforms, namely, TA2p53, TA3p53, TA4p53 and TA5p53. We also proved that TAp53 isoforms and  $\Delta 113p53$  share the same promoter and that their expressions are all induced in response to the DNA damage stress. More importantly, like  $\Delta 113p53$ , TAp53 isoforms function to antagonize the p53 apoptotic activity.

While p53 activation is important to eliminate DNA-damaged cells it is under strict control during early embryo development, mainly because aberrant activation of p53 is harmful to the process of embryogenesis (9,22). Therefore, how to cope with p53 activation during embryogenesis is an important biological question. In zebrafish, morpholino-mediated gene knockdown technique is routinely used in studying gene function during early development, however, it is often noted that injection of many gene-specific morpholinos resulted in off-target effect due to activation of the p53 pathway (16). Interestingly, the p53-activation-mediated off-target effect after morpholino injection on the injected embryos was eventually largely overcome in the following developmental stages (16). In addition, it is well doc-

umented that treatment with DNA-damage drug or ionization, or plasmid injection activates the p53 expression in the treated embryos (1,9,23). The availability of the monoclonal antibody A7-C10 allowed us to detect the status of p53 and  $\Delta 113p53$  simultaneously under the above conditions. Using this antibody we found that embryos treated with DNA-damage drugs or  $\gamma$ -irradiation or the *defhi429/hi429* mutant embryos not only displayed an elevated level of p53 but also produced  $\Delta 113p53$  and TAp53 isoforms (1). The finding that both  $\Delta 113p53$  and TAp53 isoforms function to antagonize p53 apoptotic activity nicely explains how nature has evolved a way to deal with DNA-damage-induced p53 activation during embryogenesis. Upon DNA-damage stress, p53 is activated which in turn activates the expression of the  $\Delta 113p53$  and TAp53 isoforms. Activation of  $\Delta 113p53$  and TAp53 isoforms will then protect the cells from being cleared by apoptosis and allow the cells to wait until the level of p53 is down-regulated by Mdm2. Then the cells will get a green light to re-enter the developing program. Therefore, we propose that both  $\Delta 113p53$  and TAp53 isoforms are pro-survival factors. This hypothesis is sup-



ported by the fact that CATT<sup>-/-</sup> fish (producing both the  $\Delta 113p53$  and Tap53 isoforms) is more tolerant to ionizing radiation treatment than the CATT<sup>+/+</sup> fish (producing only the  $\Delta 113p53$  isoform). In this regard, the CATT 4 bp deletion is a beneficial mutation. While we showed that the CATT 4 bp deletion is beneficial to embryos upon irradiation treatment, the individual fish we genotyped was randomly picked from the population raised in our facility. We reckon that fish growing in our fish facility are under less selection pressure, together with the consideration that CATT 4 bp deletion is probably a late event in the fish population, which might explain the ratio of CATT<sup>-/-</sup> observed in the population. It is not surprising that nature normally maximizes the use of the existing system to protect itself.

## ACCESSION NUMBER

p53 intron IV genomic DNA containing CATT 4bp deletion: KM981740; +32 bp transcript cDNA sequence: KM981741; +36 bp transcript cDNA sequence: KM981742; p53 $\beta$  cDNA sequence: KM981743.

## SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

## ACKNOWLEDGEMENT

We thank Dr Li Jan Lo for technical assistance and Drs Cherry E Ng and Mark W Zimmerman for English editing.

## FUNDING

National Natural Science Foundation of China [31330050 to J.R.P.]; "973 Program" [2012CB944550 to J.R.P.]. Funding for open access charge: National Natural Science Foundation of China [31330050 to J.R.P.].

*Conflict of interest statement.* None declared.

## REFERENCES

- Tao, T., Shi, H., Guan, Y., Huang, D., Chen, Y., Lane, D.P., Chen, J. and Peng, J. (2013) Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation. *Cell Res.*, **23**, 620–634.
- Levine, A.J. and Oren, M. (2009) The first 30 years of p53: growing ever more complex. *Nat. Rev. Cancer*, **9**, 749–758.
- Allen, M.A., Andrysk, Z., Dengler, V.L., Mellert, H.S., Guarnieri, A., Freeman, J.A., Sullivan, K.D., Galbraith, M.D., Luo, X., Kraus, W.L. et al. (2014) Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. *Elife*, **3**, e02200.
- Chen, J. and Peng, J. (2009) p53 Isoform  $\Delta 113p53$  in Zebrafish. *Zebrafish*, **6**, 389–395.
- Marcel, V., Dichtel-Danjoy, M.L., Sagne, C., Hafsi, H., Ma, D., Ortiz-Cuaran, S., Olivier, M., Hall, J., Mollereau, B., Hainaut, P. et al. (2011) Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. *Cell Death. Differ.*, **18**, 1815–1824.
- Khoury, M.P. and Bourdon, J.C. (2011) p53 isoforms: an intracellular microprocessor? *Genes Cancer*, **2**, 453–465.
- Chen, J., Ruan, H., Ng, S.M., Gao, C., Soo, H.M., Wu, W., Zhang, Z., Wen, Z., Lane, D.P. and Peng, J. (2005) Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. *Genes Dev.*, **19**, 2900–2911.
- Bourdon, J.C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D.P., Saville, M.K. and Lane, D.P. (2005) p53 isoforms can regulate p53 transcriptional activity. *Genes Dev.*, **19**, 2122–2137.
- Chen, J., Ng, S.M., Chang, C., Zhang, Z., Bourdon, J.C., Lane, D.P. and Peng, J. (2009) p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. *Genes Dev.*, **23**, 278–290.
- Marcel, V., Vijayakumar, V., Fernandez-Cuesta, L., Hafsi, H., Sagne, C., Hautefeuille, A., Olivier, M. and Hainaut, P. (2010) p53 regulates the transcription of its Delta133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. *Oncogene*, **29**, 2691–2700.
- Aoubala, M., Murray-Zmijewski, F., Khoury, M.P., Fernandes, K., Perrier, S., Bernard, H., Prats, A.C., Lane, D.P. and Bourdon, J.C. (2011) p53 directly transactivates Delta133p53alpha, regulating cell fate outcome in response to DNA damage. *Cell Death. Differ.*, **18**, 248–258.
- Ou, Z., Yin, L., Chang, C., Peng, J. and Chen, J. (2014) Protein interaction between p53 and Delta113p53 is required for the anti-apoptotic function of Delta113p53. *J. Genet. Genomics*, **41**, 53–62.
- Ebrahimi, M., Boldrup, L., Coates, P.J., Wahlin, Y.B., Bourdon, J.C. and Nylander, K. (2008) Expression of novel p53 isoforms in oral lichen planus. *Oral Oncol.*, **44**, 156–161.
- Bourdon, J.C., Khoury, M.P., Diot, A., Baker, L., Fernandes, K., Aoubala, M., Quinlan, P., Purdie, C.A., Jordan, L.B., Prats, A.C. et al. (2011) p53 mutant breast cancer patients expressing p53gamma have as good a prognosis as wild-type p53 breast cancer patients. *Breast Cancer Res.*, **13**, R7.
- Surget, S., Khoury, M.P. and Bourdon, J.C. (2013) Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. *Oncotargets. Ther.*, **7**, 57–68.
- Robu, M.E., Larson, J.D., Nasevicius, A., Beiraghi, S., Brenner, C., Farber, S.A. and Ekker, S.C. (2007) p53 activation by knockdown technologies. *PLoS. Genet.*, **3**, e78.
- Niu, X., Hong, J., Zheng, X., Melville, D.B., Knapik, E.W., Meng, A. and Peng, J. (2014) The nuclear pore complex function of Sec13 protein is required for cell survival during retinal development. *J. Biol. Chem.*, **289**, 11971–11985.
- Tao, T., Shi, H., Huang, D. and Peng, J. (2013) Def functions as a cell autonomous factor in organogenesis of digestive organs in zebrafish. *PLoS. One*, **8**, e58858.
- Wang, Y., Luo, Y., Hong, Y., Peng, J. and Lo, L. (2012) Ribosome biogenesis factor Bmsl-like is essential for liver development in zebrafish. *J. Genet. Genomics*, **39**, 451–462.
- Davidson, W.R., Kari, C., Ren, Q., Daroczi, B., Dicker, A.P. and Rodeck, U. (2010) Differential regulation of p53 function by the N-terminal DeltaNp53 and Delta113p53 isoforms in zebrafish embryos. *BMC. Dev. Biol.*, **10**, 102.
- Lee, K.C., Goh, W.L., Xu, M., Kua, N., Lunny, D., Wong, J.S., Coomber, D., Vojtesek, B., Lane, E.B. and Lane, D.P. (2008) Detection of the p53 response in zebrafish embryos using new monoclonal antibodies. *Oncogene*, **27**, 629–640.
- Montes de Oca, L.R., Wagner, D.S. and Lozano, G. (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. *Nature*, **378**, 203–206.
- Liu, J., Gong, L., Chang, C., Liu, C., Peng, J. and Chen, J. (2012) Development of novel visual-plus quantitative analysis systems for studying DNA double-strand break repairs in zebrafish. *J. Genet. Genomics*, **39**, 489–502.